Effects of Xuezhikang(血脂康) and Pravastatin on Circulating Endothelial Progenitor Cells in Patients with Essential Hypertension  

作　　者：鲁力 周建中 王丽 张铁须 

机构地区：[1]The First Affiliated Hospital of Chongqing Medical University [2]The First People's Hospital of Jiulongpo District

出　　处：《Chinese Journal of Integrative Medicine》2009年第4期266-271,共6页中国结合医学杂志（英文版）

摘　　要：Objective:To investigate the impacts of Xuezhikang(血脂康,XZK)or pravastatin combined with antihypertensive drugs on circulating endothelial progenitor cells(CEPCs)in essential hypertensive (EH)patients.Methods:Eighty-eight EH patients were enrolled into the study and randomly assigned to the antihypertensive drug treatment group(ATH group,29 cases),the pravastatin treatment group(PRA group,29 cases)and the Xuezhikang treatment group(XZK group,30 cases).Patients in the 3 groups were treated with routine antihy...Objective:To investigate the impacts of Xuezhikang(血脂康,XZK)or pravastatin combined with antihypertensive drugs on circulating endothelial progenitor cells(CEPCs)in essential hypertensive (EH)patients.Methods:Eighty-eight EH patients were enrolled into the study and randomly assigned to the antihypertensive drug treatment group(ATH group,29 cases),the pravastatin treatment group(PRA group,29 cases)and the Xuezhikang treatment group(XZK group,30 cases).Patients in the 3 groups were treated with routine antihy...

关 键 词：essential hypertension endothelial progenitor cell PRAVASTATIN Xuezhikang 

分 类 号：R544.1[医药卫生—心血管疾病]